Objective. The aim of this study was to develop an SLE disease model that simulates long-term outcomes of SLE to estimate the long-term effectiveness and cost-effectiveness of SLE treatments.
Introduction
New treatments for SLE are coming to market, or are in clinical development. It is important to understand the impact of new treatments on long-term outcomes of the disease for access and reimbursement decision-makers. This cannot be demonstrated by short-term clinical trials.
Therefore statistical models that predict long-term outcomes in SLE are needed to estimate the long-term clinical effectiveness and cost-effectiveness of new treatments. The relationship between disease activity and the long-term consequences of SLE must be quantified using modelling. Recent SLE randomized controlled clinical trials measured the reduction in disease activity or flare over a period of 1218 months [1, 2] and were not designed to measure prevention of organ damage or mortality during the relatively short trial period.
Longitudinal statistical models are used to extrapolate differences in long-term outcomes between treatments beyond the clinical trial follow-up [3] . This approach has been used in other diseases, such as diabetes, to extrapolate patient outcomes beyond clinical trials and in cost-effectiveness modelling [4] . Previous analyses in SLE have shown that disease activity and treatment predict mortality [59] and organ damage [7, 1017] . These studies, using Cox regression models, identify prognostic risk factors (such as disease activity) in order to estimate the relative effects of risk factors on survival. Analysing the relationship between intermediate and long-term outcomes has been clinically informative in past studies of risk factors in SLE, but is not optimum to simulate longterm outcomes. The shape of the survival curve must be estimated to generate models that can be used to estimate and extrapolate the probability of organ damage and mortality. The standard approach is to choose the best fitting survival curve shape that is also clinically plausible [18] . By fitting a survival model that also estimates the survival curve, it is possible to estimate the probability of an event conditional on multiple risk factors.
The aim of this study was to develop longitudinal models of disease activity and prednisone dose over time in order to subsequently simulate organ damage and mortality in cost-effectiveness models. These analyses comprise a model to extrapolate the annual average SLEDAI score, a model to estimate the annual average prednisone dose, 12 models to predict the probability of damage for each organ system and a model to predict mortality. The resulting statistical models were combined into a simulation to test the accuracy of the combined statistical models against the Hopkins Lupus Cohort. The statistical models will be most useful for predicting outcomes for patients in a health care setting like the Hopkins Lupus Cohort. Currently these analyses provide the best method to determine the long-term effectiveness and cost-effectiveness of new treatments. The statistical models were developed in collaboration with GlaxoSmithKline and were used to inform the cost-effectiveness of belimumab in the treatment of SLE.
Materials and methods

Patient population
The Hopkins Lupus Cohort contains prospective data on SLE patients from Baltimore, MD, USA. Data were extracted from the database in June 2010 (2047 patients).
Patients with follow-up of <24 months were excluded from the analysis, leaving a final sample size of 1354 (Table 1 ). The Hopkins Lupus Cohort is approved by the Johns Hopkins University School of Medicine Institutional Review Board on a yearly basis. All patients provided informed consent to participate in the cohort and all patient data were anonymized for the purpose of this analysis.
Data
The majority of patients in the Hopkins Lupus Cohort visited the clinic at least every 3 months. The Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA) SLEDAI score was recorded at each visit and organ damage was recorded using the SLICC/ACR Damage Index (SDI) [19] .
Covariate selection
The primary aim was to estimate the impact of the annual average SLEDAI on the annual average prednisone dose, and adjusted mean SLEDAI (AMS) and cumulative mean monthly prednisone dose on the risk of organ damage and mortality. Covariates were included in the models to stratify disease outcomes according to known clinical and demographic risk factors. Covariates were adjusted for confounding to isolate the effect of AMS and cumulative mean monthly prednisone on organ damage and mortality. For each outcome we specified a list of covariates based on clinical knowledge and potential confounding. Covariate selection was based on univariate proportional hazards models to identify statistically significant (P < 0.05) relationships. All significant variables were included in the multivariate regression. The final model specification was selected by backward stepwise elimination. The variable with the highest P-value was eliminated until all covariates were significant. The Akaike Information Criterion (AIC) was used to assess model fit for alternative covariate specifications. Continuous variables were assumed to be linear unless a non-linear specification improved goodness of fit or the credibility of simulated outcomes. The definitions of the variables used in the analysis and the models for which they were considered are reported in supplementary Table S1 , available at Rheumatology Online.
Annual average SLEDAI and prednisone dose
In the annual average SLEDAI model, the annual average SLEDAI score and binary variables for organ manifestations in the previous year were included, based on the literature, to describe prior disease activity [2023] . Gender, age and African American ethnicity were included to account for demographics that have been found to impact on rate of change in disease activity [24] .
The annual average prednisone dose model included covariates for annual average SLEDAI to estimate the expected increase in prednisone due to disease activity. Other demographic details, such as gender, age and African American ethnicity, were included, in line with observed prescribing patterns [25] .
Organ damage and mortality
The annual average SLEDAI model was used to extrapolate longitudinal trends in SLEDAI while the annual average prednisone dose model estimates expected prednisone exposure given the longitudinal trends in annual average SLEDAI score. The AMS and cumulative average monthly prednisone dose were considered as inputs to all of the organ damage and mortality models. The statistical models were designed to simulate longitudinal trends in the average SLEDAI and average prednisone dose and to predict organ damage and mortality related to these time-varying covariates.
The AMS was included as a time-varying measure of disease activity from cohort entry to every clinic visit adjusted by time between clinic visits and was calculated using a published AMS calculation [9] :
where S i is the SLEDAI score, t is the time interval between visit i and i À 1 and n is the number of visits in the period. Binary variables to indicate SLEDAI organ involvement at each clinic visit were included to identify correlations between organ involvement and organ damage. The binary variables were considered in all organ damage and mortality models to describe within-and between-organ involvement. Although not all SLEDAI variables described known pathways to organ damage, we included them to describe correlation between organ systems that may be due to confounding by unmeasured or unknown variables. The cumulative mean monthly prednisone dose was calculated by dividing the cumulative prednisone dose by the months of follow-up. A history of immunosuppressive treatment was included in the musculoskeletal, cardiovascular and pulmonary model following previous analysis [26] and gonadal failure based on known causal effects. Current use of HCQ was considered in all organ damage and mortality models based on previous observations [6, 27] .
Age and disease duration were implemented as log transformations to avoid linear extrapolation of risk over time when simulating older ages (>80 years) in future simulations. AIC statistics confirmed better goodness of 
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Extrapolating outcomes in SLE fit with log transformation. Age at diagnosis was included to describe the characteristics of late-onset disease [28] . Prior SDI was included as a covariate because organ damage has been shown to be a predictor of further organ damage [29] . In the mortality model, individual organ system scores at the last visit were considered. Gender and African American ethnicity were included to account for demographic effects [15, 30] . A history of smoking, obesity, cholesterol and hypertension were included to adjust for potential confounding effects of lifestyle and metabolic risks. Lupus anticoagulant and aCL were included due to observations in the literature [31] .
Statistical analysis
Annual average SLEDAI and prednisone dose
The change in annual average SLEDAI score was estimated from the previous year to the next for all years of follow-up. Annual intervals were chosen to reduce computation time in future simulation models. The annual average SLEDAI score for each period of observation was adjusted for the time between clinic visits. Linear random effects models estimated the change in annual average SLEDAI and annual average prednisone dose to account for repeated measures in the data [32] . A mathematical expression of a random effects model is reported in supplementary Table S1 , available at Rheumatology Online. The goodness of fit in these models was assessed using R 2 statistics. The appropriateness of the random effects model was tested by observing the fraction of variance due to the random effects error. Analyses were run in STATA 11 [33] (StataCorp, College Station, TX, USA) using the XTREG command.
Organ damage and mortality
The definition of organ damage was based on the SDI [34] . The SDI includes 41 non-reversible items grouped into 12 components: cardiovascular, renal, musculoskeletal, pulmonary, peripheral vascular, gastrointestinal, ocular, skin and neuropsychiatric and three domains of diabetes, gonadal failure and malignancy. The damage analyses were grouped by organ system because the costs and health implications of damage events vary across organ systems. Parametric survival analyses were performed to estimate the time to organ damage and mortality. The models included time-varying covariates. Four forms of the survival analysis were considered (exponential, Weibull, Gompertz and log-logistic), which allow different assumptions to be made about the shape of the survival curve. Details of the parametric distributions considered can be found in supplementary Table S1 , available at Rheumatology Online. Frailty models were tested to describe patient heterogeneity. The survival curves were chosen according to recommended goodness of fit criteria [18] , i.e. the AIC and CoxSnell residuals [35] . The analysis was conducted using the STREG command in STATA 11 [33] .
Sensitivity analysis
Sensitivity analyses were conducted on these models. First, analyses were conducted for borderline significant covariates (P-value > 0.05 to < 0.1) to investigate whether the covariate had a substantial effect on the AMS or cumulative prednisone coefficient. Second, musculoskeletal, neuropsychiatric, cardiovascular and pulmonary organ damage events were split into subgroups to determine whether alternative covariates were selected.
Simulation methods
An individual patient simulation was developed in Simul8 (Simul8, Boston, MA, USA) to demonstrate how the statistical models could be used and to test whether the statistical models produced biased estimates of disease outcomes [36] . A sample of 100 000 patients whose baseline characteristics matched the Hopkins Lupus Cohort was generated. In every annual cycle of the model the patient's disease activity score was updated using the annual average SLEDAI model. The expected change in annual average SLEDAI score for the next year was calculated from a linear equation with estimates taken from Table 2 .
The reduced model for prednisone dose was chosen for the simulation for simplicity. The probability of an event occurring in each cycle of the model was generated from the equation
where H(t) is the cumulative hazard function for the current time and H(t À 1) is the cumulative hazard for the previous period. The formulae for the cumulative hazard depend on the parametric distribution and are described in the supplementary material, available at Rheumatology Online. Time of withdrawal from the simulation was estimated from a Weibull distribution.
Results
We developed 14 longitudinal statistical models to predict long-term outcomes for SLE patients. When combined, the models simulate a patient's expected disease activity trajectory, prednisone exposure and the timing of organ damage and mortality.
Annual average SLEDAI
The model predicting the change in annual average SLEDAI can be used to extrapolate longitudinal trends in SLEDAI by age, adjusting for other disease and demographic characteristics (Table 2) . Annual average SLEDAI scores declined with age. The annual average SLEDAI score in the previous period was associated with a decrease in annual average SLEDAI following treatment and management of the disease. The decrease in annual average SLEDAI score was greater in patients with renal involvement, older patients and males. African American ethnicity, anaemia, haematological involvement, increased DNA binding and low complement predicted increases in the annual average SLEDAI score for the next year.
Prednisone dose
The annual average prednisone dose model estimates the expected prednisone exposure given the longitudinal trends in the annual average SLEDAI score. The prednisone dose model confirmed the positive relationship between annual average SLEDAI score and annual average prednisone dose ( Table 2 ). The regression coefficients suggest that younger patients, African Americans and males had higher annual average prednisone doses.
Organ damage and mortality
The organ damage and mortality models estimated the probability of important events given the patient's disease activity and prednisone exposure. Table 3 reports risk models derived for mortality and organ damage. The hazard ratios and time ratios can be used to generate probabilities of these events, conditional on patient characteristics (see the supplementary material, available at Rheumatology Online). Hazard ratios are reported for the exponential, Weibull and Gompertz models (Table 3) . Time ratios express the effect of covariates in the log-logistic models and should be interpreted as the factor by which the time to failure is multiplied for a unit change in the covariate. Time ratios of <1 shorten the time to an event. The frailty models were not used in the final specification because there were no significant frailty effects. The mortality model is described by a Weibull distribution, suggesting an increasing risk of mortality over time. The mortality model predicts the time of death for a patient according to ethnicity, age, cholesterol level, AMS, organ involvement, organ damage, malignancy, infection and HCQ dose. A higher AMS and haematological involvement were significant risk factors for mortality.
Traditional risk factors for cardiovascular events such as age at diagnosis, disease duration, hypertension and cholesterol were significant in this SLE population. AMS and serositis involvement were statistically significant predictors of cardiovascular damage. Cumulative average prednisone dose had a weak relationship. AMS and renal involvement had a significant effect in increasing the risk of renal damage. Cumulative average prednisone dose, a history of immunosuppressive treatment, age and TABLE 3 Parameter estimates for the baseline hazard, additional distribution parameters and impact of covariates on long-term outcomes using HRs and time ratios Cardio: cardiovascular; Gastro: gastrointestinal; Gonadal: Gonadal failure; HR: hazard ratio; MSK: musculoskeletal; Neuro: neuropsychiatric; P vascular: peripheral vascular.
previous damage had a significant association with musculoskeletal damage. Neuropsychiatric involvement, cholesterol, hypertension, log of age and cumulative average prednisone dose were associated with neuropsychiatric damage. The analyses for pulmonary damage found that serositis, increased DNA binding and renal involvement were all significant risk factors. umulative average prednisone dose and aCL were also associated with a higher risk of pulmonary damage. Smoking, cholesterol and lupus anticoagulant were significantly related to peripheral vascular damage. Mean prednisone dose and vasculitis were associated with gastrointestinal damage. Age was a strong and significant predictor of ocular damage. Mean monthly prednisone dose and neuropsychiatric involvement were retained in the ocular model. African American ethnicity, smoking and skin involvement predicted shorter time to skin damage, whereas HCQ increased time to skin damage. Age, African American ethnicity, prednisone dose and renal involvement were associated with diabetes. High cholesterol, disease duration, increased age at diagnosis, history of cytotoxic treatment and previous damage were predictors of malignancy. Cholesterol, prednisone and cytotoxic treatment predicted gonadal failure.
Sensitivity analysis (results not reported here)
We did not identify any covariates whose exclusion caused the coefficient estimates for AMS or cumulative average prednisone to change by >10%. Therefore excluding these variables was unlikely to have caused confounding bias in our estimates.
Subgroup analysis of musculoskeletal, neuropsychiatric, cardiovascular and ocular damage events suggested that pooling items by organ system did not substantially affect covariate selection and coefficient estimates. Table 4 details the simulation cohort summary statistics and the outcomes of the hypothetical cohort. The simulated data produce non-statistically significant differences for most outcomes reported in Table 4 . A statistically significant difference in SLEDAI score is observed at the end of follow-up. Fig. 1 illustrates the differences between the proportion of patients with organ-specific damage or death at the end of follow-up observed in the Hopkins Lupus Cohort and the simulation cohort and reports P-values (z-test). The simulated prevalence of mortality and renal, pulmonary, vascular, ocular and skin damage at the last visit were not significantly different, whereas cardiovascular, musculoskeletal and neuropsychiatric damage were significantly different (Fig. 1) . Although the simulation does not perfectly fit all organ outcomes, given the complexity of the disease, the fit is reasonable.
Simulation model
Discussion
The emergence of new biologic therapies for SLE has increased clinical and regulatory interest in the clinical effectiveness and cost-effectiveness of these agents. We developed and tested statistical models for the natural history of disease activity and prednisone use in patients with SLE, together with a set of statistical risk models for mortality and 12 types of organ damage for an SLE population treated in a speciality clinic. The models enable the user to estimate the likelihood of long-term complications over the lifetime of a patient with and without a new treatment and are necessary to evaluate the long-term effectiveness of interventions. Previous studies have not analysed the impact of disease activity and prednisone dose on all of the organ systems of the SDI and mortality using the same observational dataset. Furthermore, previous studies have employed Cox regression models Consistent with the published literature, we identified that AMS, organ-specific disease activity and treatment impact the probability of organ damage and mortality [12, 14, 37] . The results estimated that AMS increased the risk of death, cardiovascular damage and renal damage. In many of the organ damage models, disease activity in a particular organ system had a strong association with organ damage within the same organ system, e.g. skin involvement with skin damage. The analyses found that cumulative average prednisone dose increased the risk of cardiovascular damage, musculoskeletal damage, gastrointestinal damage, neuropsychiatric damage, ocular damage, diabetes and gonadal failure.
In our organ damage models we included covariates for disease activity and prednisone, where statistically significant, to isolate the independent effects of disease activity and prednisone on damage accumulation. Treatment practice for corticosteroid use varies between practitioners. In the Hopkins Lupus Cohort, increased use of corticosteroids is associated with increased risk of organ damage. However, the association may be influenced by the treatment choices at this centre. It is challenging to describe the complex relationships between prednisone dose and organ damage given the positive and negative effects it may have. There is evidence that corticosteroid use has a protective effect on plaque formation, most likely due to reduction in inflammatory disease [38] . However, on balance the overall effect of steroids on cardiovascular outcomes and organ damage is detrimental in other large SLE registries [10, 39] . A key challenge is to clarify how best to describe the burden and patterns of corticosteroid doses in epidemiology studies. Cumulative average prednisone was chosen in this analysis based on the findings of previous analyses of the Hopkins Lupus Cohort [16] . Patient adherence to treatment was not included in this analysis because it could not be reliably assessed from self-reported adherence. Furthermore, extrapolation of the statistical models to other contexts may be more difficult if adherence data are not available in other settings. Nevertheless, adherence to treatment may be an important contributor to long-term outcomes, prednisone exposure and i.v. therapy, which should be explored in future analyses.
The SLEDAI score was chosen to measure disease activity because of its association with risk of organ damage and mortality and the Hopkins Lupus Cohort has recorded SLEDAI scores for >25 years. The Physicians Global Assessment (PGA) and the BILAG are included in the SLE Responder Index, but were not included in these analyses [40] . A limitation of the SLEDAI is that it does not credit partial improvement or worsening in a particular domain that is already present [41] . SLEDAI was modelled as a composite score to simplify the computation burden of the simulation.
Grouping events by organ system was a reasonable form of damage classification, but it has limitations. Developing predictive models for each individual item in an organ domain of the SDI was not possible given the small number of events observed for some items. Furthermore, we needed to simplify the disease to reduce model complexity and the computational burden   FIG. 1 The proportion of patients who recorded mortality or organ damage at the time of withdrawal from follow-up of future simulation models. Sensitivity analyses indicated that our model system captures most risk factors for events within the organ systems.
There are a variety of ways to build a regression model, each with strengths and weaknesses. We identified candidate covariates based on clinical opinion, known associations from previous studies and to correct for possible confounding. We used backward selection using statistical significance tests to select the final list of covariates in the model and the AIC for goodness of fit. However, this approach may not be sufficient to avoid model overfitting.
The Hopkins Lupus Cohort provided a large longitudinal dataset of SLE patients and has no interoperator variability between observations, strengthening the observed associations in the natural history disease model. However, achieving external validity from the analysis of a single cohort of SLE patients is challenging because of variability in demographic profiles, different treatment practices, frequency of clinic visits, follow-up duration, socio-economic factors and environment factors. The Hopkins Lupus Cohort has a significant proportion of African Americans and individuals from lower socio-economic backgrounds. The mean SLEDAI score at cohort entry is lower than that seen in other SLE cohorts, such as the Toronto cohort [12] and SLICC inception cohort [42] . Demographic covariates were included in the models, but were not always significant. Care must be taken in applying this natural history model to alternative populations. Further research is needed to externally validate these analyses against other datasets.
In conclusion, this study developed a set of statistical models to simulate SLE patient outcomes for different baseline characteristics. The models can be used to estimate the probability of an event for individual patients and evaluate the long-term effectiveness and cost-effectiveness of new emerging treatments. These models are a starting point for the simulation of SLE. Further research should test alternative statistical methods and analyse other SLE populations.
Rheumatology key message
. We can estimate long-term SLE outcomes according to patient characteristics, disease activity and treatments.
